Seoulin Bioscience Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
May 16, 2022 at 02:26 am EDT
Share
Seoulin Bioscience Co.,Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was KRW 34.05 million compared to KRW 112.19 million a year ago. Net income was KRW 2,058.36 million compared to KRW 1,484.2 million a year ago.
Basic earnings per share from continuing operations was KRW 245.0046 compared to KRW 176.6766 a year ago. Diluted earnings per share from continuing operations was KRW 241.1001 compared to KRW 176.6766 a year ago. Basic earnings per share was KRW 245.0046 compared to KRW 176.6766 a year ago.
Seoulin Bioscience Co., Ltd is a Korea-based company engaged in the developing and manufacturing of basic equipment for bio research. The Company mainly engages in research and development of reagents, such as deoxyribonucleic acid (DNA) chips, which are used for gene therapy, clinical diagnosis, organs transplantation and biopsy; stem cells, which are used for treatment of incurable diseases, Alzheimer disease and others, and next-generation biotechnology drugs. The company supplies its products under the brand name MyLab. It also imports bio research equipment from Thermo Fisher, Affymetrix, Sarstedt and others, and markets in the domestic market. In addition, the Company engages in the real estate rental business.
SEOULIN BIOSCIENCE CO.,LTD. 
